Expand all sections

Triamcinolone

Zilretta

Extended indication Osteoarthritis van de knie
Therapeutic value Possible equal value
Total cost 62,500.00
Registration phase Clinical trials

Product

Active substance Triamcinolone
Domain Chronic immune diseases
Reason of inclusion New medicine (specialité)
Main indication Other chronic immune diseases
Extended indication Osteoarthritis van de knie
Proprietary name Zilretta
Manufacturer Flexion
Mechanism of action Corticosteroid
Route of administration Intra-articular
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks Triamcinolone acetonide extended-release injectable suspension, a corticosteroid with anti-inflammatory and immunomodulating properties. Pipeline watch 12 januari 2018: Clinical benefits after repeat administration. Phase 3 Interim/Top-line Results.

Registration

Registration route Centralised (EMA)
Submission date 2021
Expected Registration 2022
Orphan drug No
Registration phase Clinical trials
Additional remarks Betamethason, methylprednisolon, triamcinolonacetonide

Therapeutic value

Therapeutic value Possible equal value
Substantiation De werkgroep verwacht geen grote impact. De verwachting is dat dit een deel van de huidige behandelingen zal overnemen.
Dosage per administration 40 mg
References NCT02357459
Additional remarks Eenmalige injectie

Expected patient volume per year

Patient volume

< 2,500

Market share is generally not included unless otherwise stated.
References Voklsgezondheidenzorg.nl; NIVEL zorgregistraties eerste lijn; Barten et al.BMC Fam Pract 2015)
Additional remarks In 2016 werd naar schatting bij 54.900 mensen knieartrose gediagnostiseerd. De prevalentie in 2016 bedroeg 571.600 patiënten. In 5% van de gevallen wordt door de huisarts een intra-articulaire injectie met corticosteroïden toegediend. De verwachting is dat deze nieuwe formulering van triamcinolon bij een deel van deze gevallen zal worden ingezet.

Expected cost per patient per year

Cost 25.00
References GIPdatabank
Additional remarks Vergoeding per gebruiker voor betamethason, methylprednisolon, triamcinolonacetonide in 2016 betreft €24,50

Potential total cost per year

Total cost

62,500.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.